What is the recommended treatment for herpes simplex virus type 1 (HSV‑1) oral cold sores in adults?

Treatment of Cold Sores (Herpes Labialis)

For oral cold sores in adults, initiate oral valacyclovir 2 g twice daily for 1 day at the first sign of prodromal tingling or within 24–48 hours of lesion onset for optimal efficacy. 1

First-Line Episodic Treatment

Early treatment is critical—antiviral therapy must be started during the prodromal phase (tingling, burning sensation) or within 24–48 hours of visible lesions to achieve meaningful clinical benefit. 1 Delayed treatment beyond this window provides minimal benefit. 2, 3

Recommended Oral Antiviral Regimens (in order of convenience and efficacy):

• Valacyclovir 2 g orally twice daily for 1 day (single-day therapy)—most convenient high-dose regimen with superior healing time and pain resolution 1

• Famciclovir 1500 mg orally as a single dose—comparable efficacy to high-dose valacyclovir 1

• Acyclovir 400 mg orally 5 times daily for 5 days—effective alternative when valacyclovir or famciclovir unavailable 3, 1

• Acyclovir 800 mg orally twice daily for 5 days—alternative dosing 3

• Acyclovir 200 mg orally 5 times daily for 5 days—older regimen, less convenient 2, 3

Valacyclovir and famciclovir offer superior convenience due to less frequent dosing and higher oral bioavailability compared to acyclovir, though they cost more and lack pediatric approval. 4 The single-day or single-dose regimens dramatically improve adherence while maintaining efficacy. 1

Suppressive Therapy for Frequent Recurrences

Consider daily suppressive therapy for patients experiencing ≥6 recurrences per year or episodes causing significant psychological distress. 1

Recommended Suppressive Regimens:

• Valacyclovir 500 mg orally once daily (preferred for convenience) 1

• Acyclovir 400 mg orally twice daily 3, 1

• Famciclovir 250 mg orally twice daily 3, 1

Suppressive therapy reduces recurrence frequency by ≥75% and has documented safety for continuous use up to 6 years with acyclovir. 3, 1 However, it does not completely eliminate asymptomatic viral shedding or transmission risk. 3, 1

Re-evaluate the need for suppressive therapy after 1 year, as natural recurrence rates decline over time in many patients. 3, 1 Acyclovir resistance is not clinically significant in immunocompetent patients. 3, 1

Topical Therapy (Limited Role)

Topical antivirals are substantially less effective than oral therapy and should only be used when systemic treatment is contraindicated. 3

• Acyclovir 5% cream applied 5 times daily for 4–5 days may modestly reduce lesion duration if applied very early 1, 5

• Acyclovir 5% + hydrocortisone 1% cream (applied 5 times daily for 5 days) may provide additional benefit by reducing inflammatory response 6

• Penciclovir 1% cream and docosanol 10% cream are alternatives but offer minimal advantage over acyclovir cream 7

Topical agents do not prevent recurrences and should never be used for suppressive therapy. 1

Special Populations

Immunocompromised Patients (including HIV)

Use higher doses and longer treatment courses—short 1–3 day regimens are inadequate. 1

• Episodic treatment: Valacyclovir 500 mg orally twice daily for 5–14 days 1 or acyclovir 400 mg orally 3–5 times daily until clinical resolution 1

• Suppressive therapy: Valacyclovir 500 mg orally twice daily (not once daily) 1 or acyclovir 400 mg orally 3–5 times daily 1

Acyclovir-Resistant HSV-1

Suspect resistance if lesions fail to improve within 7–10 days of standard therapy, particularly in immunocompromised patients on prolonged antiviral treatment. 1, 8

• Confirm with viral culture and susceptibility testing 1

• IV foscarnet is the treatment of choice for confirmed resistance 1, 8

• Topical cidofovir or trifluridine may be applied for 21–28 days for external lesions 1

Pregnancy

Acyclovir is the preferred antiviral during pregnancy due to the most extensive safety data. 1 Episodic treatment is acceptable; routine suppressive therapy is not recommended unless disease is severe. 1

Severe Disease

For disseminated infection, encephalitis, pneumonitis, or hepatitis requiring hospitalization, administer IV acyclovir 5–10 mg/kg every 8 hours for 5–7 days or until clinical resolution. 2, 3, 1

Critical Patient Education

Provide patients with advance prescriptions to enable immediate self-initiated treatment at the first prodromal symptom—this is the single most important factor determining treatment success. 1 Delayed treatment provides minimal benefit. 2, 3

Counsel patients that:

• Lesions are contagious during active outbreaks 3, 1
• Asymptomatic viral shedding can occur even between episodes 3, 1
• Sunscreen (SPF ≥15) may help prevent UV-triggered recurrences 5

Common Pitfalls to Avoid

• Do not delay treatment—waiting until vesicles are fully formed negates most antiviral benefit 1
• Do not rely on topical therapy alone in immunocompetent patients when oral therapy is available 3
• Do not use short-course regimens in immunocompromised patients 1
• Do not continue suppressive therapy indefinitely without reassessment at 1 year 3, 1